FDA approves CT LUCIA 621P Monofocal IOL from ZEISS

The U.S. Food and Drug Administration (FDA) has approved the CT LUCIA 621P Monofocal IOL, an aspheric, monofocal, single-piece C-loop IOL, according to a press release. This IOL features the patented ZEISS Optic Asphericity Concept, which compensates for a wide range of spherical aberrations, optimizing visual outcomes in the event of potential decentration and lens misalignments.

The CT LUCIA 621P Monofocal IOL is a part of the ZEISS cataract workflow solution portfolio, which helps surgeons provide optimized visual outcomes for cataract patients. The IOL comes in a fully preloaded injector, enabling an intuitive, smooth, and controlled injection. The IOL’s architecture is designed to enable easy centering while maximizing direct capsular contact, ensuring stability and supporting a consistent position in the bag.

With the FDA’s approval, the CT LUCIA 621P Monofocal IOL is now available for use in the United States.